Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140018/S049

VenaSeal Closure System

Medtronic Vascular, Inc. · Decision date Apr 17, 2026

FDA DECISIONP140018/S049

What did the FDA decide?

FDA records P140018/S049 as a supplement to PMA P140018, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 17, 2026.

FDA approval order statement

an alternate primary biological indicator for use in the dry heat sterilization process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Apr 17, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140018/S049
Regulatory pathway
PMA supplement
Product code
PJQ
Decision code
OK30
Decision date
Apr 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, occluding, vascular, permanent.

Product code
PJQ
FDA device class
3

For the original device and its historical approval scope, see PMA P140018. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140018 · Original PMA

    VENASEAL CLOSURE SYSTEM

  2. P140018/S046 · Related supplement

    VenaSeal Closure System

  3. P140018/S047 · Related supplement

    VenaSeal Closure System

  4. P140018/S048 · Related supplement

    VenaSeal Closure System

  5. P140018/S049 received

    Application receipt date recorded by FDA.

  6. P140018/S049 · FDA decision

    30-Day Notice

  7. P140018/S050 · Related supplement

    VenaSeal Closure System

Timeline entries are records held by MedtechLedger for P140018. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140018

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Vascular, Inc.PMA approvalFeb 20, 2015FDA
Medtronic Vascular, Inc.PMA supplementSep 23, 2025FDA
Medtronic Vascular, Inc.PMA supplementSep 26, 2025FDA
Medtronic Vascular, Inc.PMA supplementMar 11, 2026FDA
Medtronic Vascular, Inc.PMA supplementOct 15, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3033 Campus Dr., Plymouth, MN, 55441

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records